Literature DB >> 3663884

Prediction of steady-state bioequivalence relationships using single dose data I-linear kinetics.

A J Jackson1.   

Abstract

Simulated data using a linear one- and two-compartment body model with different absorption characteristics were used to evaluate the ability of single dose bioavailability data to predict the relationships that exist at steady state. This was done by comparing the confidence intervals obtained from single and multiple dose data sets for the parameters of Tmax, Cmax, and area under the curve from time zero to infinity (AUC0-infinity). As a consequence of Tmax and Cmax decreasing and increasing from single to multiple dosing regimens, the confidence intervals for these parameters reflected these changes. The 90 per cent confidence interval expressed as a percentage of the reference mean increased or decreased for Tmax dependent upon the ratio of Ka test/Ka reference, and decreased for Cmax while the interval for AUC0-infinity exhibited no predictable pattern and appeared to be influenced by the amount of error in the data set. Alteration of either the dosing interval or the fraction absorbed did not affect the pattern of change in the confidence intervals for Tmax and Cmax, but the latter did result in a decrease in the interval for AUC0-infinity. Analysis of the confidence intervals for Tmax, Cmax and AUC0-infinity in bioequivalency studies for quinidine gluconate and procainamide hydrochloride following administration of single and multiple doses to different subjects appeared to be consistent with the patterns observed for the simulated data sets.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663884     DOI: 10.1002/bdd.2510080508

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  10 in total

1.  Estimation of Cmax and Tmax in populations after single and multiple drug administrations.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-10       Impact factor: 2.745

2.  The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect.

Authors:  M L Chen; A J Jackson
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 3.  Bioavailability and bioequivalence: focus on physiological factors and variability.

Authors:  Vangelis Karalis; Panos Macheras; Achiel Van Peer; Vinod P Shah
Journal:  Pharm Res       Date:  2008-06-13       Impact factor: 4.200

Review 4.  Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi; Alfredo Garcia Arieta
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  The Two Main Goals of Bioequivalence Studies.

Authors:  Laszlo Endrenyi; Henning H Blume; Laszlo Tothfalusi
Journal:  AAPS J       Date:  2017-02-02       Impact factor: 4.009

Review 6.  Metrics for the evaluation of bioequivalence of modified-release formulations.

Authors:  Laszlo Endrenyi; Laszlo Tothfalusi
Journal:  AAPS J       Date:  2012-08-22       Impact factor: 4.009

7.  The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect.

Authors:  M L Chen; A J Jackson
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

8.  Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo simulations.

Authors:  A A el-Tahtawy; A J Jackson; T M Ludden
Journal:  Pharm Res       Date:  1994-09       Impact factor: 4.200

9.  Multiple-Dose Studies can be a More Sensitive Assessment for Bioequivalence than Single-Dose Studies : The Case with Omeprazole.

Authors:  Zeev Elkoshi; Dan Behr; Alex Mirimsky; Igor Tsvetkov; Abraham Danon
Journal:  Clin Drug Investig       Date:  2002-09       Impact factor: 2.859

10.  Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.

Authors:  Michel Berg; Timothy E Welty; Barry E Gidal; Francisco J Diaz; Ron Krebill; Jerzy P Szaflarski; Barbara A Dworetzky; John R Pollard; Edmund J Elder; Wenlei Jiang; Xiaohui Jiang; Regina D Switzer; Michael D Privitera
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.